Neuraltus has a number of compounds in the pipeline, including a drug to treat Amyotropic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease; a drug that will reduce dyskinesias (jerky involuntary movements) in patients suffering from Parkinson’s disease; and a drug to treat lysosomal storage disorders. Neuraltus is currently focused on conducting and completing Phase 1 and Phase 2 clinical trials for these disorders.